BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11900878)

  • 1. Genetic and environmental factors in cutaneous malignant melanoma.
    Bressac-de-Paillerets B; Avril MF; Chompret A; Demenais F
    Biochimie; 2002 Jan; 84(1):67-74. PubMed ID: 11900878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
    Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
    Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic susceptibility in familial melanoma from northeastern Italy.
    Landi MT; Goldstein AM; Tsang S; Munroe D; Modi W; Ter-Minassian M; Steighner R; Dean M; Metheny N; Staats B; Agatep R; Hogg D; Calista D
    J Med Genet; 2004 Jul; 41(7):557-66. PubMed ID: 15235029
    [No Abstract]   [Full Text] [Related]  

  • 7. Genes involved in melanoma: an overview of INK4a and other loci.
    Castellano M; Parmiani G
    Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial cutaneous melanoma.
    Hansson J
    Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
    Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
    Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
    Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
    Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
    Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
    Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
    Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
    Soufir N; Basset-Seguin N
    Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
    Celebi JT; Ward KM; Wanner M; Polsky D; Kopf AW
    Clin Exp Dermatol; 2005 Jan; 30(1):68-70. PubMed ID: 15663508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of melanoma predisposition.
    Hayward NK
    Oncogene; 2003 May; 22(20):3053-62. PubMed ID: 12789280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for the development of primary cutaneous malignant melanoma.
    MacKie RM
    Dermatol Clin; 2002 Oct; 20(4):597-600. PubMed ID: 12380046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.